LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Facts and Hopes in Immunotherapy of Endometrial Cancer.

    Marín-Jiménez, Juan A / García-Mulero, Sandra / Matías-Guiu, Xavier / Piulats, Josep M

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2022  Volume 28, Issue 22, Page(s) 4849–4860

    Abstract: Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is not an exception. Approved treatment options are pembrolizumab or dostarlimab for mismatch repair deficient tumors, pembrolizumab ...

    Abstract Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is not an exception. Approved treatment options are pembrolizumab or dostarlimab for mismatch repair deficient tumors, pembrolizumab for tumors with high mutational load, and, more recently, pembrolizumab/lenvatinib for all patients with endometrial cancer. Endometrial cancer is a heterogeneous disease with distinct molecular subtypes and different prognoses. Differences between molecular subgroups regarding antigenicity and immunogenicity should be relevant to develop more tailored immunotherapeutic approaches. In this review, we aim to summarize and discuss the current evidence-Facts, and future opportunities-Hopes-of immunotherapy for endometrial cancer, focusing on relevant molecular and tumor microenvironment features of The Cancer Genome Atlas endometrial cancer subtypes.
    MeSH term(s) Female ; Humans ; Immunotherapy ; Endometrial Neoplasms/drug therapy ; Endometrial Neoplasms/genetics ; Tumor Microenvironment ; Immunologic Factors/therapeutic use
    Chemical Substances dostarlimab ; Immunologic Factors
    Language English
    Publishing date 2022-07-05
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-21-1564
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.

    Linares, Jenniffer / Marín-Jiménez, Juan A / Badia-Ramentol, Jordi / Calon, Alexandre

    Frontiers in cell and developmental biology

    2021  Volume 8, Page(s) 621070

    Abstract: Multiple lines of evidence are indicating that cancer development and malignant progression are not exclusively epithelial cancer cell-autonomous processes but may also depend on crosstalk with the surrounding tumor microenvironment (TME). Cancer- ... ...

    Abstract Multiple lines of evidence are indicating that cancer development and malignant progression are not exclusively epithelial cancer cell-autonomous processes but may also depend on crosstalk with the surrounding tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) are abundantly represented in the TME and are continuously interacting with cancer cells. CAFs are regulating key mechanisms during progression to metastasis and response to treatment by enhancing cancer cells survival and aggressiveness. The latest advances in CAFs biology are pointing to CAFs-secreted factors as druggable targets and companion tools for cancer diagnosis and prognosis. Especially, extensive research conducted in the recent years has underscored the potential of several cytokines as actionable biomarkers that are currently evaluated in the clinical setting. In this review, we explore the current understanding of CAFs secretome determinants and functions to discuss their clinical implication in oncology.
    Language English
    Publishing date 2021-01-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2737824-X
    ISSN 2296-634X
    ISSN 2296-634X
    DOI 10.3389/fcell.2020.621070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread.

    Gendrau-Sanclemente, Núria / Figueras, Agnès / Gracova, Kristina / Lahiguera, Álvaro / Alsina-Sanchís, Elisenda / Marín-Jiménez, Juan A / Vidal, August / Matias-Guiu, Xavier / Fernandez-Gonzalez, Sergi / Barahona, Marc / Martí, Lola / Ponce, Jordi / Viñals, Francesc

    Molecular oncology

    2023  Volume 18, Issue 1, Page(s) 136–155

    Abstract: High-grade serous ovarian cancer (HGSOC) is the deadliest gynecological malignancy. The most common form of metastatic spread of HGSOC is transcoelomic dissemination. In this process, detached cells from the primary tumor aggregate as tumorspheres and ... ...

    Abstract High-grade serous ovarian cancer (HGSOC) is the deadliest gynecological malignancy. The most common form of metastatic spread of HGSOC is transcoelomic dissemination. In this process, detached cells from the primary tumor aggregate as tumorspheres and promote the accumulation of peritoneal ascites. This represents an early event in HGSOC development and is indicative of poor prognosis. In this study, based on tumorspheres isolated from ascitic liquid samples from HGSOC patients, ovarian cancer spheroid 3D cultures, and in vivo models, we describe a key signal for tumorsphere formation in HGSOC. We report that platelet-derived growth factor receptor beta (PDGFRβ) is essential for fibronectin-mediated cell clustering of ovarian cancer cells into tumorspheres. This effect is mediated by the kinase NUAK family SNF1-like kinase 1 (NUAK1) and blocked by PDGFRβ pharmacological or genetic inhibition. In the absence of PDGFRβ, ovarian cancer cells can be provided with fibronectin by cancer-associated fibroblasts to generate chimeric spheroids. This work provides new insights that uncover potential targets to prevent peritoneal dissemination, the main cause of advanced disease in HGSOC patients.
    MeSH term(s) Humans ; Female ; Fibronectins ; Ovarian Neoplasms/pathology ; Ascites/pathology ; Ascitic Fluid/metabolism ; Cancer-Associated Fibroblasts/metabolism ; Protein Kinases ; Repressor Proteins
    Chemical Substances Fibronectins ; NUAK1 protein, human (EC 2.7.1.-) ; Protein Kinases (EC 2.7.-) ; Repressor Proteins
    Language English
    Publishing date 2023-12-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2415106-3
    ISSN 1878-0261 ; 1574-7891
    ISSN (online) 1878-0261
    ISSN 1574-7891
    DOI 10.1002/1878-0261.13556
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6637: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors.

    Lanis, Jordi M / Lewis, Matthew S / Strassburger, Hannah / Larsen, Kristina / Bagby, Stacey M / Dominguez, Adrian T A / Marín-Jiménez, Juan A / Pelanda, Roberta / Pitts, Todd M / Lang, Julie

    Journal of visualized experiments : JoVE

    2022  , Issue 190

    Abstract: Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer from poor translation to the ... ...

    Abstract Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer from poor translation to the clinic. To serve as a more physiological preclinical model for immunotherapy studies, this protocol has been developed to evaluate the treatment of human tumors in a mouse reconstituted with a human immune system. This unique protocol demonstrates the development of human immune system (HIS, "humanized") mice, followed by implantation of a human tumor, either a cell-line derived xenograft (CDX) or a patient derived xenograft (PDX). HIS mice are generated by injecting CD34+ human hematopoietic stem cells isolated from umbilical cord blood into neonatal BRGS (BALB/c Rag2
    MeSH term(s) Humans ; Animals ; Mice ; Xenograft Model Antitumor Assays ; Mice, Inbred NOD ; Neoplasms/pathology ; Transplantation, Heterologous ; Immunotherapy/methods ; Disease Models, Animal ; Tumor Microenvironment
    Language English
    Publishing date 2022-12-16
    Publishing country United States
    Document type Journal Article ; Video-Audio Media ; Research Support, N.I.H., Extramural
    ZDB-ID 2259946-0
    ISSN 1940-087X ; 1940-087X
    ISSN (online) 1940-087X
    ISSN 1940-087X
    DOI 10.3791/64606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.

    Marín-Jiménez, Juan A / Oliva, Marc / Peinado Martín, Paloma / Cabezas-Camarero, Santiago / Plana Serrahima, Maria / Vázquez Masedo, Gonzalo / Lozano Borbalas, Alicia / Cabrera Martín, María N / Esteve, Anna / Iglesias Moreno, María C / Vilajosana Altamis, Esther / Arribas Hortigüela, Lorena / Taberna Sanz, Miren / Pérez-Segura, Pedro / Mesía, Ricard

    Frontiers in oncology

    2022  Volume 12, Page(s) 953020

    Abstract: Objectives: Induction chemotherapy (ICT) followed by definitive treatment is an accepted non-surgical approach for locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, ICT remains a challenge for cisplatin-unfit patients. ... ...

    Abstract Objectives: Induction chemotherapy (ICT) followed by definitive treatment is an accepted non-surgical approach for locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, ICT remains a challenge for cisplatin-unfit patients. We evaluated paclitaxel and cetuximab (P-C) as ICT in a cohort of LA-HNSCC patients unfit for cisplatin.
    Materials and methods: This is a retrospective analysis of patients with newly diagnosed LA-HNSCC considered unfit for cisplatin-based chemotherapy (age >70 and/or ECOG≥2 and/or comorbidities) treated with weekly P-C followed by definitive radiotherapy and cetuximab (RT-C) between 2010 and 2017. Toxicity and objective response rate (ORR) to ICT and RT-C were collected. Median overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Cox regression analysis was performed to determine baseline predictors of OS and PFS.
    Results: A total of 57 patients were included. Grade 3-4 toxicity rate to ICT was 54.4%, and there was a death deemed treatment-related (G5). P-C achieved an ORR of 66.7%, including 12.3% of complete responses (CR). After P-C, 45 patients (78.9%) continued with concomitant RT-C. Twenty-six patients (45.6%) achieved a CR after definitive treatment. With a median follow-up of 21.7 months (range 1.2-94.6), median OS and PFS were 22.9 months and 10.7 months, respectively. The estimated 2-year OS and PFS rates were 48.9% and 33.7%, respectively. Disease stage had a negative impact on OS (stage IVb vs. III-IVa: HR = 2.55 [1.08-6.04],
    Conclusion: P-C was a well-tolerated and active ICT regimen in this cohort of LA-HNSCC patients unfit for cisplatin-based chemotherapy. P-C might represent a valid ICT option for unfit patients and may aid patient selection for definitive treatment.
    Language English
    Publishing date 2022-07-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.953020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models.

    Lang, Julie / Leal, Alexis D / Marín-Jiménez, Juan A / Hartman, Sarah J / Shulman, Jeremy / Navarro, Natalie M / Lewis, Matthew S / Capasso, Anna / Bagby, Stacey M / Yacob, Bethlehem W / MacBeth, Morgan / Freed, Brian M / Eckhardt, S Gail / Jordan, Kimberly / Blatchford, Patrick J / Pelanda, Roberta / Lieu, Christopher H / Messersmith, Wells A / Pitts, Todd M

    Frontiers in oncology

    2022  Volume 12, Page(s) 877635

    Abstract: Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecule ... ...

    Abstract Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecule multi-tyrosine kinase inhibitor that is FDA approved in advanced renal cell, medullary thyroid, and hepatocellular carcinoma. Using Human Immune System (HIS) mice, we tested the ability of cabozantinib to prime MSS-CRC tumors to enhance the potency of immune checkpoint inhibitor nivolumab. In four independent experiments, we implanted distinct MSS-CRC patient-derived xenografts (PDXs) into the flanks of humanized BALB/c-Rag2
    Language English
    Publishing date 2022-11-07
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.877635
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.

    Marín-Jiménez, Juan A / Capasso, Anna / Lewis, Matthew S / Bagby, Stacey M / Hartman, Sarah J / Shulman, Jeremy / Navarro, Natalie M / Yu, Hui / Rivard, Chris J / Wang, Xiaoguang / Barkow, Jessica C / Geng, Degui / Kar, Adwitiya / Yingst, Ashley / Tufa, Dejene M / Dolan, James T / Blatchford, Patrick J / Freed, Brian M / Torres, Raul M /
    Davila, Eduardo / Slansky, Jill E / Pelanda, Roberta / Eckhardt, S Gail / Messersmith, Wells A / Diamond, Jennifer R / Lieu, Christopher H / Verneris, Michael R / Wang, Jing H / Kiseljak-Vassiliades, Katja / Pitts, Todd M / Lang, Julie

    Frontiers in immunology

    2021  Volume 12, Page(s) 607282

    Abstract: Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of ... ...

    Abstract Over the past decade, immunotherapies have revolutionized the treatment of cancer. Although the success of immunotherapy is remarkable, it is still limited to a subset of patients. More than 1500 clinical trials are currently ongoing with a goal of improving the efficacy of immunotherapy through co-administration of other agents. Preclinical, small-animal models are strongly desired to increase the pace of scientific discovery, while reducing the cost of combination drug testing in humans. Human immune system (HIS) mice are highly immune-deficient mouse recipients rtpeconstituted with human hematopoietic stem cells. These HIS-mice are capable of growing human tumor cell lines and patient-derived tumor xenografts. This model allows rapid testing of multiple, immune-related therapeutics for tumors originating from unique clinical samples. Using a cord blood-derived HIS-BALB/c-Rag2
    MeSH term(s) Animals ; Chimerism ; Disease Models, Animal ; Hematopoietic Stem Cell Transplantation ; Heterografts ; Humans ; Immune System ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Lymphocyte Subsets/immunology ; Lymphocyte Subsets/metabolism ; Lymphoid Tissue/immunology ; Lymphoid Tissue/metabolism ; Mice ; Mice, Inbred NOD ; Mice, Knockout ; Mice, SCID ; Neoplasms/etiology ; Neoplasms/immunology ; Neoplasms/therapy ; Phenotype ; Xenograft Model Antitumor Assays
    Language English
    Publishing date 2021-03-29
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.607282
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top